Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of December 2022, specifically reporting on a public equity offering that closed on December 23, 2022. The Company, a foreign private issuer, executed a securities purchase agreement to raise capital through the sale of ordinary shares.
Key Financial Metrics
- Gross Proceeds: $14,500,002
- Shares Issued: 8,787,880 ordinary shares
- Offering Price: $1.65 per share
- Placement Fees: 7.0% of gross proceeds (3.0% for certain identified investors)
- Expenses: $50,000 for accountable expenses and $10,000 for non-accountable expenses
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net profit, operating cash flow, or margins as this is a transactional filing rather than a periodic financial report.
- Debt/Liquidity: The filing text does not provide a clear value for total debt or existing liquidity positions prior to this offering.
Material Changes
The primary material change reported is the increase in equity capital and share count resulting from the public offering. The Company issued approximately 8.79 million new shares, increasing its outstanding share count and cash reserves by the gross proceeds amount. No comparative period financial data is provided in this document to assess year-over-year or quarter-over-quarter operational changes.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful closing of the offering pursuant to a prospectus supplement dated December 21, 2022, under a shelf registration statement (Form F-3). The transaction was executed at-the-market under Nasdaq rules.
Risks and Contingencies: The filing references customary indemnification provisions within the Placement Agency Agreement but does not detail specific new operational risks or contingencies beyond the standard disclosures associated with equity offerings.
Guidance: The filing text does not provide a clear value for future financial guidance or operational outlook.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7.0% placement fees and $60,000 in expenses.
- Confirm the updated total number of outstanding ordinary shares post-offering.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any specific covenants or restrictions on the use of proceeds.
- Check the press release (Exhibit 99.1) for management's stated intended use of the raised capital.
- Confirm the identity of the "certain identified investors" eligible for the reduced 3.0% placement fee.